Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
Health
Storm Newton

NHS watchdog to review evidence on two pioneering Alzheimer’s drugs

The national health spending watchdog is set to re-evaluate its decision on two pioneering Alzheimer's drugs following successful appeals from their manufacturers.

Donanemab and lecanemab, licensed for use in the UK in 2024, were initially deemed too expensive for NHS provision by the National Institute for Health and Care Excellence (Nice).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.